EX-99.1

Safe Harbor Statement

Certain statements contained in this release are forward-looking statements and are based on future

expectations, plans and prospects for InfuSystem Holdings, Inc.’s (“InfuSystem”, “INFU”, “the Company”,

“We”) business and operations that involve a number of risks and uncertainties. InfuSystem’s outlook for

2013 and other forward-looking statements in this release are made as of December 5, 2013, and the

Company disclaims any duty to supplement, update or revise such statements on a going-forward basis,

whether as a result of subsequent developments, changed expectations or otherwise. In connection with the

“safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying

certain factors that could cause actual results to differ, perhaps materially, from those indicated by these

forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential

changes in overall healthcare reimbursement – including CMS competitive bidding, sequestration,

concentration of customers, increased focus on early detection of cancer, competitive treatments,

dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions,

changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers,

risks in acquisitions & joint ventures, US Healthcare Reform, relationships with healthcare professionals and

organizations, technological changes related to infusion therapy, dependency on websites and intellectual

property, the ability of the Company to successfully integrate acquired businesses, dependency on key

personnel, dependency on banking relations and covenants, and other risks associated with our common

stock, as well as any other litigation to which the Company may be subject from time to time; and other risk

factors as discussed in the Company’s annual report on Form 10-K for the year ended December 31, 2012 and

in other filings made by the Company from time to time with the Securities and Exchange Commission.

Innovative provider and supplier of

infusion services

Market leader in oncology home

infusion with 40,000 patients a year

–

25 Year business model

World-class pump rentals and

service to providers, manufacturers,

and other rental companies in the

US and Canada

46,000 InfuSystem pump fleet

generating revenue from both

payors and providers

InfuSystem at a Glance

2013 9-Month Financials

Revenues $45.1M (Up 6%)

AEBITDA $11.5M (Up 8%)

Free Cash Flow $9.2M (Up 73%)

Market Cap $37.65M @ $1.72

Company Overview

InfuSystem Niche –

Extension of Clinic to Home

Ambulatory Home Infusion

25-year old business model in

DME billing

At home, at work, at play, all

while receiving the drug

High satisfaction scores

24/7 on-call oncology nurses

Proven outcomes with

continuous home infusion

Oncology, Post Surgical Pain,

Special Disease States

TPP Payor Contracts

Bills patient insurance

250+ Commercial and

Government Payor

Contracts

Commercial Payors

reimburse more

therapies than CMS

Awarded contracts in

all 9

MSAs (1 of 3

National Vendors)

Average cuts of ~21%

for our category, per

CMS ($250,000 per yr)

Rentals, Sales & Service to Providers

Pump Rentals, Sales and

Asset Management

Pump Experts

Direct sales, rental, and

lease of device and

supplies in US and

Canada

Pump Broker Expertise –

ability to acquire and

dispose of CAP EX in cost

effective way

Asset management,

rental and lease

Preventative Maint.

Annual Pump

Recertification

Preventative

Maintenance

Warranty

Repair

World-Class ISO

Certified service

facilities

Regional Distribution

West, South, East &

Canada

28 Certified Technicians

Financial Overview

(1)

Free

Cash

Flow

Adjusted

EBITDA

less

CapEx

and

Purchases

Medical

Equipment

$38,964

$47,229

$54,637

$58,828

$56,793

$60,137

$30m

$40m

$50m

$60m

$70m

FY2009

FY2010

FY2011

FY2012

9M 2012

Annualized

9M 2013

Annualized

Revenues

Growing

$10,256

$13,126

$13,969

$15,028

$6m

$10m

$14m

$18m

FY2011

FY2012

9M 2012

Annualized

9M 2013

Annualized

AEBITDA

Growing

$5,754

$10,568

$12,915

$14,244

$4m

$8m

$12m

$16m

FY2011

FY2012

9M 2012

Annualized

9M 2013

Annualized

FCF

Growing

$2,931

$2,226 `

$2,935

$7,211

$6,249

$5,537

$5,955

$0m

$2m

$4m

$6m

$8m

1Q 2012

2Q 2012

3Q 2012

4Q 2012

1Q 2013

2Q 2013

3Q 2013

Liquidity

Improved

Revenues

Adjusted EBITDA

Free Cash Flow (1)

Unrestricted Liquidity

Uses of Free Cash Flow

(1)

Free

Cash

Flow

Adjusted

EBITDA

less

CapEx

and

Purchases

Medical

Equipment

$24,141

$32,197

$29,127

$31,268

$28,466

$28,328

$27,619

$20m

$25m

$30m

$35m

FY2009

FY2010

FY2011

FY2012

1Q 2013

2Q 2013

3Q 2013

Debt

Declining

$31,734

$34,193

$35,026

$35,474

$37,040

$30m

$32m

$34m

$36m

$38m

FY2011

FY2012

Q1 2013

Q2 2013

Q3 2013

Rental Fleet

Increasing

Total Debt

PP&E and Medical Equipment in Service (at cost)

Every

$1.00

invested

the rental fleet returns

~$1.50 in revenue

every

year

for

the

life of the pump

Compelling Value Proposition

In-House Service & Repairs

Convenience & Flexibility

Pre-Owned Equipment Expertise

One-Stop Shopping Solution

Convenience and flexibility of rentals and

financing minimize customer capital outlays

Rental and financing eliminates the need for

in-house maintenance/service

Option

own,

rent

finance

–

designed

fit

customers’

operating and financial parameters

Shorter and longer-term financing options

One-stop shopping solution for ambulatory large

volume pump and other movable medical devices

Sales

Rentals

Supplies

Service

Financing

World-class biomedical repair and

service for pumps, defibrillators and

most other general medical

equipment

Allows InfuSystem to purchase, clean,

repair and certify any used medical

equipment the Company buys for

subsequent sale, rental or financing to

customers

“ONE-STOP SHOP”

SERVICE &

REPAIRS

CONVENIENCE &

FLEXIBILITY

PRE-OWNED

EQUIPMENT

EXPERTISE

Unique ability to source and deploy pre-

owned movable medical equipment

Consistent, fair and knowledgeable

market maker for pre-owned pump

disposals

Market knowledge results in attractive

equipment acquisition costs

Complementary core competencies allow InfuSystem to offer superior selection, flexibility, pricing and services

Payor & Customer Mix

Leading Cancer Institution Customers

Revenue by Payor (FY2012)

High diversification of providers and payors

No single healthcare provider represents more than 7% of Third-Party Payor revenues

Strong payor mix among Medicare, other commercial insurers, Blue Cross/Blue Shield, and Medicaid

Less

than

revenues

received

directly

from

patients

through

co-pays

otherwise

Broad coverage further diversifies revenue streams

InfuSystem has strong relationships with the largest third-party payors and the leading cancer institutions

9 of 10 of the Top

Ten Cancer

Treatment Centers

Medicare and

Medicaid

37%

BCBS

19%

Patient

Commercial

38%

CMS: Centers for Medicare and Medicaid Services

Competitive Landscape

InfuSystem measures its market

share not in terms of the number of

practices, but the pool of

addressable patients

The breakdown of the Company’s

current market share shows that

despite being the predominant

national player in continuous

infusion, there is ample room for

organic growth

The Company competes for market

share in all but the Captive Health

Plans which represent health plans

in which all

services are rendered

by one common payor/provider

(e.g., Kaiser Permanente)

Market Share for Oncology Continuous Infusion

Source: American Cancer Society, CMS, National Comprehensive Cancer

Network, National Home Infusion Association

InfuSystem

32%

Home Infusion Providers

32%

Facility Owned Pumps

11%

Competitor DME Providers

10%

Disposable

Pumps

Captive Health Plan

14%

InfuSystem’s Direct Payor business is focused primarily on the sale, rental, financing and accompanying service of

movable

medical

equipment

hospitals

and

alternate

care

sites

who

pay

InfuSystem

directly

–

third-party

reimbursement

Founded in 1998 and headquartered in Olathe, KS with distribution/service centers in Santa Fe Springs, CA and

Mississauga, Ontario

InfuSystem

services –

ISO

9001

and

repairs

movable

medical

equipment

Leading provider to alternate site healthcare facilities and hospitals in the United States and Canada

Home infusion providers, long-term care, physician clinics, research facilities, etc.

Transacts

directly

with

healthcare

providers

–

third-party

reimbursement

revenue

Infusion pumps

Enteral pumps

Direct Payor Business Model

Service & Repair

Products

InfuSystem sells, rents and finances a wide variety of new

and used large volume and ambulatory pumps

InfuSystem services and repairs both its own fleet of

pumps and many types of other movable medical

equipment

Syringe pumps

Ambulatory pumps

Large volume pumps

Ambulatory pumps

Fluid collection

Medical equipment

InfuSystem offers new pumps from top brands

Broker-dealer trading desk

In addition, over 70 models and versions of pre-owned pumps

are offered

Pre-owned pumps are re-built and certified by in-house

biomedical technicians to be patient ready

Warranty offered on pre-owned pumps

A variety of financing options to fit customers’

operating,

budgeting and financing parameters

Nationwide, industry-leading ISO 9001 service programs

Launching branch service center in Houston

Direct Payor Offerings

Renting new or pre-owned equipment

Rent pumps by the day, week or month to

match swings in patient count

Free shipping on all rentals

Industry leader in sales of pre-owned

equipment, creating significant savings

Competitive pricing on new equipment

Option to sell back pre-owned pumps

Leasing plans offered

ISO 9001 Service offered

Service plans offered

Local service expansion

2 existing; 1 planned

Coordinate with TPP

Loaner pumps available

Pre-Owned & New Pumps from Top Manufacturers

Leading Provider of New and Pre-Owned Pumps

Full Spectrum of Ownership Options for Customers

Rental

Sales

Asset Management

Medical Equipment Service & Repair

In addition to supporting and repairing

InfuSystem’s in-house fleet, the Company certifies,

recalibrates, repairs and services a variety of

infusion pumps

Pumps require scheduled maintenance and

calibration in accordance with manufacturer’s

specifications and regulatory guidelines

Service and repair capabilities on high demand

services reaching end of life that are no longer

supported by manufacturers

ISO certification and an established quality system

strengthens relationships with major customers

Provides InfuSystem an opportunity to establish a

business relationship with customers that acquired

pumps through other sources

Continuing and increased need for compliance

with current as well as anticipated regulations

28 highly qualified service technicians

5 major manufacturer relationships:

3 service centers, located in California,

Toronto and Kansas

Ambulatory Pump Rental Fleet

With over 26,000+ pumps in TPP Rental Fleet, InfuSystem maintains the largest fleet of

ambulatory infusion pumps in the industry

DPP Rental Fleet has over 20,000 pumps

The Company has a complete inventory of virtually every model pump from every leading

manufacturer, allowing InfuSystem to provide the right pump for any patient’s prescribed

protocol

Purchases of pumps have a high return on investment and an useful life of 10-15 years

All Rentals (Both DP and TPP) -

YE 2011

YE 2012

Q1 2013

Q2 2013

Q3 2013

Rental Revenue ($K)

$ 46,795

$ 53,471

$ 13,445

$ 13,618

$ 14,493

Medical

Equipment

Service

Cost

($K)

$ 31,734

$ 34,193

$ 35,026

$ 35,474

$ 37,040

Rental Revenue Per Dollar of

Medical

Equipment

Service

Invested

–

Annualized

$ 1.47

$ 1.56

$ 1.54

$ 1.57

Annual Rental Revenue per $1 Rental Fleet Cost (“Revenue Ratio”)

Competitive Bidding Overview

InfuSystem was not involved in Round 1 nor

Round 2 of Competitive Bidding

CMS announced a Recompete of Round 1

competitive bidding on April 17th

External infusion pumps/supplies added as a

new product category

A supplier must bid on all items within the

product category to have its RFP considered

Recompete covers 9 Metropolitan Statistical

Areas (MSAs)

Competitive Bidding Overview

InfuSystem’s Response to Competitive Bidding

InfuSystem has engaged consultants and industry

professionals to discuss directly with CMS, advise

on positioning the Company for potential

regulatory changes, and facilitate potential

strategic partnership opportunities

InfuSystem was awarded contracts in all 9 MSAs

with average cuts of ~21% for our category per

CMS. 1 of 3 National Vendors to receive

contracts in all 9 markets.

“Competitive environment will vary in accordance

with the level of cuts by CMS”

CMS

Competitive

Bidding

“Target”

Timetable

CMS will institute some form of competitive

bidding nationwide by January 2016.

CMS began the pre-

bidding supplier

awareness program

CMS announced bidding

schedule, start bidder

education and begin a

bidder registration period

Bid window

opens

Current Round 1 bid

contracts expire

CMS announces Round

1 Recompete bid

results –

INFU impact

$250K annually

Bid window

closes

Implementation of

Round 1 bid contracts

and prices

Spring

2012

08/16/12

10/15/12

12/14/12

10/1/13

12/31/13

01/01/14

Summary Income Statement

($000's)

FY2009

FY2010

FY2011

FY2012

9 Mo 2012

9 Mo 2013

Net revenues:

Rentals

46,795

53,471

38,903

41,556

Product sales

7,842

5,357

3,692

3,547

Net revenues

38,964

47,229

54,637

58,828

42,595

45,103

Cost of revenues:

Product, service and supply costs

6,200

7,730

9,128

9,165

6,760

8,174

Pump depreciation and loss on disposal

4,127

5,954

10,154

6,752

4,928

4,836

Gross profit

35,355

42,911

30,907

32,093

Provision for doubtful accounts

4,006

4,515

4,099

5,251

3,119

4,782

Amortization of intangibles

1,827

2,259

2,662

2,734

2,028

1,972

Asset impairment charges

67,592

Selling and marketing

5,258

7,087

9,371

9,864

7,635

7,281

General and administrative

12,218

20,622

17,987

23,062

17,688

14,622

Operating income (loss)

5,328

(938)

(66,356)

2,000

437

3,436

Total other (loss)

(3,577)

(2,285)

(2,221)

(4,152)

(2,921)

(2,307)

Loss before income taxes

1,751

(3,223)

(68,577)

(2,152)

(2,484)

1,129

Income tax benefit

(977)

1,371

23,134

663

774

(324)

Net income (loss)

774

(1,852)

(45,443)

(1,489)

(1,710)

805

EBITDA

11,199

7,745

(57,336)

9,590

6,122

9,747

EBITDA (ex. Impairment Charges)

11,199

7,745

10,256

9,590

6,122

9,747

Adjusted EBITDA

10,256

13,126

10,477

11,271

Summary Balance Sheet

($000's)

12/31/09

12/31/10

12/31/11

12/31/12

3/31/13

6/30/13

9/30/13

ASSETS

Current Assets:

Cash and cash equivalents

7,750

5,014

799

2,326

472

102

908

Account receivable - total, net of allowance

5,517

6,679

7,448

8,511

9,570

9,440

9,291

Inventory

925

1,699

1,309

1,339

1,378

1,379

1,343

Prepaid expenses and other current assets

395

750

934

684

832

713

625

Deferred income taxes

125

1,147

682

1,971

1,986

Total Current Assets

14,712

15,289

11,172

14,831

14,238

13,620

14,153

Total PP&E and Medical Equipment

13,499

16,672

17,672

16,564

16,653

17,958

18,749

Deferred debt issuance costs, net

781

658

421

2,362

2,232

2,106

1,972

Total Goodwill and Intangible assets, net

85,491

97,344

28,221

25,541

24,871

24,221

24,075

Deferred income taxes

18,187

17,806

17,755

17,689

17,259

Other assets

207

401

590

419

477

157

184

Total Assets

114,690

130,364

76,263

77,523

76,226

75,751

76,392

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Account payable - total

1,306

2,016

4,063

2,144

3,056

3,833

4,329

Accrued expenses and other

1,573

4,631

2,235

4,098

4,182

2,782

2,824

Derivative liabilities

2,670

183

258

Current portion of long-term debt

5,501

5,551

6,576

3,953

3,872

3,124

3,239

Total Current Liabilities

11,050

12,381

13,132

10,195

11,110

9,739

10,392

Long Term Debt, net of current portion

18,640

26,646

22,551

27,315

24,594

25,204

24,380

Deferred income taxes

3,314

5,788

Other Liabilities

221

406

415

Total Liabilities

33,225

45,221

36,098

37,510

35,704

34,943

34,772

Total Stockholderrs' Equity

81,465

85,143

40,165

40,013

40,522

40,808

41,620

Total Liabilities and Equity

114,690

130,364

76,263

77,523

76,226

75,751

76,392

Total Debt

24,141

32,197

29,127

31,268

28,466

28,328

27,619

Cash Flow

($000's)

FY2009

FY2010

FY2011

FY2012

9 Mo 2012

9 Mo 2013

OPERATING ACTIVITIES

Net Income

774

(1,852)

(45,443)

(1,489)

Adjustments:

Provision for doubtful accounts

4,006

4,515

4,099

5,251

Depreciation

4,122

5,357

6,386

5,668

Loss on disposal of pumps

342

994

1,731

237

Amortization of intangible assets

1,827

2,259

2,662

2,734

Asset impairment charges

67,592

Stock-based compensation

753

3,860

1,185

964

Total Other Adjustments

2,827

(1,581)

(26,021)

(1,971)

Changes in assets and liabilities (ex. acquisitions)

(4,943)

(2,740)

(5,445)

(5,942)

NET CASH PROVIDED BY OPERATING ACTIVITIES

9,708

10,812

6,746

5,452

5,834

4,765

INVESTING ACTIVITIES

Total Purchases of PP&E, Med. Eq., and Other Assets, net

(4,611)

(2,444)

(4,502)

(2,558)

(791)

(588)

Acquisition of intangible assets

(625)

Cash paid for acquisition, net of cash acquired

(16,616)

NET CASH PROVIDED BY INVESTING ACTIVITIES

(4,611)

(19,060)

(5,127)

(2,558)

(791)

(588)

FINANCING ACTIVITIES

Net Borrowing on term loan, revolver, and capital leases

(8,565)

7,377

(5,369)

1,619

(4,247)

(5,517)

Capitalized debt issuance costs

(808)

(2,842)

Common stock withholding on stock based compensation

(135)

(167)

(102)

(144)

(131)

(78)

Treasury shares repurchased

(68)

(363)

Principal payments on capital lease obligations

(160)

(822)

NET CASH PROVIDED BY FINANCING ACTIVITIES

(8,860)

5,512

(5,834)

(1,367)

(4,378)

(5,595)

Net change in cash and cash equivalents

(3,763)

(2,736)

(4,215)

1,527

665

(1,418)

Cash and cash equivalents, beginning of period

11,513

7,750

5,014

799

2,326

Cash and cash equivalents, end of period

7,750

5,014

799

2,326

1,464

908

Free Cash Flow (EBITDA less CapEx & Purchases of ME)

6,588

5,301

5,754

7,032

5,331

9,159

Free Cash Flow (Adj. EBITDA less CapEx & Purchases of ME)

5,754

10,568

9,686

10,683

Revenue Growth (%)

21.2

15.7

7.7

5.9